91 related articles for article (PubMed ID: 7841310)
1. Large-scale preparation of highly purified human C1-inhibitor for therapeutic use.
Poulle M; Burnouf-Radosevich M; Burnouf T
Blood Coagul Fibrinolysis; 1994 Aug; 5(4):543-9. PubMed ID: 7841310
[TBL] [Abstract][Full Text] [Related]
2. In vitro study of a triple-secured von Willebrand factor concentrate.
Mazurier C; Poulle M; Samor B; Hilbert L; Chtourou S
Vox Sang; 2004 Feb; 86(2):100-4. PubMed ID: 15023178
[TBL] [Abstract][Full Text] [Related]
3. Purification of human ceruloplasmin as a by-product of C1-inhibitor.
Kouoh Elombo F; Radosevich M; Poulle M; Descamps J; Chtourou S; Burnouf T; Catteau JP; Bernier JL; Cotelle N
Biol Pharm Bull; 2000 Dec; 23(12):1406-9. PubMed ID: 11145166
[TBL] [Abstract][Full Text] [Related]
4. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
Schwinn H; Smith A; Wolter D
Arzneimittelforschung; 1989 Oct; 39(10):1302-5. PubMed ID: 2514695
[TBL] [Abstract][Full Text] [Related]
5. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
7. Purification of C1 inhibitor. A new approach for the isolation of this biologically important plasma protease inhibitor.
Prograis LJ; Hammer CH; Katusha K; Frank MM
J Immunol Methods; 1987 May; 99(1):113-22. PubMed ID: 3553333
[TBL] [Abstract][Full Text] [Related]
8. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
9. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII.
Foster PR; Griffin BD; Bienek C; McIntosh RV; MacGregor IR; Somerville RA; Steele PJ; Reichl HE
Vox Sang; 2004 Feb; 86(2):92-9. PubMed ID: 15023177
[TBL] [Abstract][Full Text] [Related]
10. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
Caballero S; Nieto S; Gajardo R; Jorquera JI
Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
[TBL] [Abstract][Full Text] [Related]
11. The first component of complement. I. Purification and properties of native C1.
Medicus RG; Chapuis RM
J Immunol; 1980 Jul; 125(1):390-5. PubMed ID: 7381205
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the chromatographic procedure for the preparation of a high-purity C1-esterase inhibitor concentrate from cryosupernatant plasma.
Teh LC; Froger M
J Chromatogr; 1992 Nov; 582(1-2):65-70. PubMed ID: 1491059
[TBL] [Abstract][Full Text] [Related]
13. Comparison of membrane adsorber (MA) based purification schemes for the down-stream processing of recombinant h-AT III.
Reif OW; Freitag R
Bioseparation; 1994 Dec; 4(6):369-81. PubMed ID: 7765681
[TBL] [Abstract][Full Text] [Related]
14. A modification of an affinity procedure for purification of human C1- inhibitor that provides a homogeneous stable preparation.
Donaldson VH; Falconieri MW
J Immunol Methods; 1993 Jan; 157(1-2):101-4. PubMed ID: 8423351
[TBL] [Abstract][Full Text] [Related]
15. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
[TBL] [Abstract][Full Text] [Related]
16. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement.
Fischer MB; Prodeus AP; Nicholson-Weller A; Ma M; Murrow J; Reid RR; Warren HB; Lage AL; Moore FD; Rosen FS; Carroll MC
J Immunol; 1997 Jul; 159(2):976-82. PubMed ID: 9218619
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional structure and molecular modelling of C1- inhibitor.
Perkins SJ
Behring Inst Mitt; 1993 Dec; (93):63-80. PubMed ID: 8172587
[TBL] [Abstract][Full Text] [Related]
18. C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema. Strong correlation with the severity of disease in C1-INH concentrate naïve patients.
Varga L; Széplaki G; Visy B; Füst G; Harmat G; Miklós K; Németh J; Cervenak L; Karádi I; Farkas H
Mol Immunol; 2007 Feb; 44(6):1454-60. PubMed ID: 16750855
[TBL] [Abstract][Full Text] [Related]
19. Progress in large-scale purification of factor VIII/von Willebrand factor concentrates using ion-exchange chromatography.
Mori F; Nardini I; Rossi P; Nardini C; Farina C
Vox Sang; 2008 Nov; 95(4):298-307. PubMed ID: 19138259
[TBL] [Abstract][Full Text] [Related]
20. Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction.
Thielmann M; Marggraf G; Neuhäuser M; Forkel J; Herold U; Kamler M; Massoudy P; Jakob H
Eur J Cardiothorac Surg; 2006 Aug; 30(2):285-93. PubMed ID: 16829095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
